BG107762A - Радиофармацевтични средства за диагностициране болестта на алцхаймер - Google Patents

Радиофармацевтични средства за диагностициране болестта на алцхаймер

Info

Publication number
BG107762A
BG107762A BG107762A BG10776203A BG107762A BG 107762 A BG107762 A BG 107762A BG 107762 A BG107762 A BG 107762A BG 10776203 A BG10776203 A BG 10776203A BG 107762 A BG107762 A BG 107762A
Authority
BG
Bulgaria
Prior art keywords
radiopharmaceuticals
alzheimer
disease diagnostics
disease
diagnostics
Prior art date
Application number
BG107762A
Other languages
Bulgarian (bg)
English (en)
Inventor
Christoph-Steph Hilger
Bernd Johannsen
Jorg Steinbach
Peter Maeding
Meredith Halks-Miller
Richard Horuk
Harald Dinter
Raju Mohan
Joseph E. Hesselgesser
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Publication of BG107762A publication Critical patent/BG107762A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BG107762A 2000-11-06 2003-04-25 Радиофармацевтични средства за диагностициране болестта на алцхаймер BG107762A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24629900P 2000-11-06 2000-11-06
PCT/EP2001/012607 WO2002036581A1 (en) 2000-11-06 2001-11-01 Radiopharmaceuticals for diagnosing alzheimer's disease

Publications (1)

Publication Number Publication Date
BG107762A true BG107762A (bg) 2004-03-31

Family

ID=22930075

Family Applications (1)

Application Number Title Priority Date Filing Date
BG107762A BG107762A (bg) 2000-11-06 2003-04-25 Радиофармацевтични средства за диагностициране болестта на алцхаймер

Country Status (29)

Country Link
US (2) US6676926B2 (de)
EP (1) EP1332138B1 (de)
JP (1) JP4234425B2 (de)
KR (1) KR20030045167A (de)
CN (1) CN1473158A (de)
AR (1) AR035366A1 (de)
AT (1) ATE314354T1 (de)
AU (2) AU1403402A (de)
BG (1) BG107762A (de)
BR (1) BR0115150A (de)
CA (1) CA2424598A1 (de)
DE (1) DE60116365T2 (de)
EA (1) EA006199B1 (de)
EE (1) EE200300216A (de)
HR (1) HRP20030459A2 (de)
HU (1) HUP0301710A3 (de)
IL (1) IL155191A0 (de)
JO (1) JO2207B1 (de)
MX (1) MXPA03003759A (de)
NO (1) NO20032007L (de)
NZ (1) NZ525303A (de)
PE (1) PE20020531A1 (de)
PL (1) PL361631A1 (de)
SK (1) SK287495B6 (de)
TW (1) TWI238820B (de)
UY (1) UY27003A1 (de)
WO (1) WO2002036581A1 (de)
YU (1) YU33203A (de)
ZA (1) ZA200304409B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY27003A1 (es) * 2000-11-06 2002-07-31 Schering Ag Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer
CZ2004519A3 (cs) 2001-10-22 2004-12-15 Pfizer Products Inc. Deriváty piperazinu s účinky antagonisty receptoru CCR1
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
AU2002351412B2 (en) 2001-12-21 2010-05-20 Exelixis Patent Company Llc Modulators of LXR
PL1620373T3 (pl) * 2003-05-07 2008-09-30 Bayer Schering Pharma Ag Urządzenie i sposób fluorowania nukleofilowego
EP2610234A1 (de) * 2004-02-24 2013-07-03 The General Hospital Corporation Katalytische Radiofluorierung
US9017724B2 (en) 2004-02-24 2015-04-28 The General Hospital Corporation Catalytic radiofluorination
US8257680B1 (en) 2004-02-24 2012-09-04 The General Hospital Corporation Catalytic radiofluorination
GB0409236D0 (en) * 2004-04-26 2004-05-26 Novartis Ag Organic compounds
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
KR100778888B1 (ko) * 2005-11-29 2007-11-28 재단법인서울대학교산학협력재단 베타아밀로이드 펩타이드 플라크의 영상화를 위한벤질리덴아닐린 계열의 유도체 및 그의 방사성 동위원소표지화합물
KR20090066289A (ko) 2006-09-08 2009-06-23 로드아일랜드하스피틀 알코올 유발성 뇌 질환의 치료, 예방 및 역행
CA2663115C (en) 2006-09-08 2015-04-28 Rhode Island Hospital Treatment, prevention, and reversal of alcohol-induced liver disease
GB0625523D0 (en) 2006-12-21 2007-01-31 Ge Healthcare Ltd In vivo imaging agents
EP2094625A1 (de) * 2006-12-21 2009-09-02 Hammersmith Imanet, Ltd Verfahren zur radioaktiven markierung
CA2703563A1 (en) * 2007-10-31 2009-05-07 Alseres Pharmaceuticals, Inc. Methods for diagnosing and monitoring treatment of lewy body dementia by assessing dopamine transporter level
US8450466B2 (en) 2008-03-21 2013-05-28 The General Hosptial Corporation Compounds and compositions for the detection and treatment of Alzheimer's disease and related disorders
EP2161256A1 (de) * 2008-09-08 2010-03-10 Atomic Energy Council - Institute of Nuclear Energy Research Verbindung mit Carboxylat-Ester und bifunktionalen N2S2-Liganden-Gruppen und Herstellungsverfahren davon
EP2163541A1 (de) * 2008-09-12 2010-03-17 Bayer Schering Pharma Aktiengesellschaft Piperazin-Derivate zur Bindung und Abbildung von Amyloidplaques und deren Verwendung
US20110077222A1 (en) * 2009-09-30 2011-03-31 Mallinckrodt Inc. Sustained-Release Opiate and Opiate Derivative Compositions
TW201201846A (en) * 2010-02-08 2012-01-16 Bayer Schering Pharma Ag Iodo precursor for a PET imaging agent of amyloid plaques
WO2011110511A1 (en) * 2010-03-11 2011-09-15 Bayer Pharma Aktiengesellschaft Spect imaging agents of amyloid plaques
US9572787B2 (en) 2011-05-19 2017-02-21 Rhode Island Hospital Inhibition of renal fibrosis
JP6584322B2 (ja) 2013-12-27 2019-10-02 国立大学法人 東京医科歯科大学 アルツハイマー病及び前頭側頭葉変性症の診断方法、診断薬、治療薬、及びこれら薬剤のスクリーニング方法
EP3340796B1 (de) * 2015-08-28 2021-04-21 CHDI Foundation, Inc. Sonden zur bildgebung von huntingtin-protein

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU654013B2 (en) 1991-03-13 1994-10-20 Regents Of The University Of Minnesota 2-hydroxy-3(4-iodophenyl)-1-(4-phenylpiperidinyl) propane
EP0524146A1 (de) 1991-07-19 1993-01-20 Ciba-Geigy Ag Aminosubstituierte Piperazinderivate
GB9413772D0 (en) 1994-07-08 1994-08-24 Wyeth John & Brother Ltd 5-HT1A ligands
AU2680797A (en) * 1996-04-24 1997-11-12 Emory University Halogenated naphthyl methoxy piperidines for mapping serotonin transporter sites
US6281212B1 (en) 1996-07-12 2001-08-28 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
FR2758328B1 (fr) 1997-01-15 1999-04-02 Pf Medicament Nouvelles amines aromatiques derivees d'amines cycliques utiles comme medicaments
US6207665B1 (en) * 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
AUPP278498A0 (en) * 1998-04-03 1998-04-30 Australian Nuclear Science & Technology Organisation Peripheral benzodiazepine receptor binding agents
US6288083B1 (en) 1998-09-04 2001-09-11 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
AUPP818099A0 (en) 1999-01-14 1999-02-11 Fujisawa Pharmaceutical Co., Ltd. New n-containing heterocyclic compounds
EE200100502A (et) 1999-03-26 2002-12-16 Astrazeneca Ab Ühendid
UY27003A1 (es) * 2000-11-06 2002-07-31 Schering Ag Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer

Also Published As

Publication number Publication date
AU2002214034B2 (en) 2006-01-05
EP1332138B1 (de) 2005-12-28
MXPA03003759A (es) 2003-07-28
NZ525303A (en) 2004-10-29
JP2004513123A (ja) 2004-04-30
PL361631A1 (en) 2004-10-04
US20020131932A1 (en) 2002-09-19
SK287495B6 (sk) 2010-12-07
UY27003A1 (es) 2002-07-31
HUP0301710A2 (hu) 2003-11-28
ZA200304409B (en) 2004-09-06
CA2424598A1 (en) 2002-05-10
SK5472003A3 (en) 2003-10-07
CN1473158A (zh) 2004-02-04
JO2207B1 (en) 2004-10-07
BR0115150A (pt) 2003-12-30
US6676926B2 (en) 2004-01-13
EA200300507A1 (ru) 2003-12-25
NO20032007L (no) 2003-07-02
PE20020531A1 (es) 2002-06-15
WO2002036581A1 (en) 2002-05-10
TWI238820B (en) 2005-09-01
NO20032007D0 (no) 2003-05-05
JP4234425B2 (ja) 2009-03-04
AR035366A1 (es) 2004-05-12
US6872381B1 (en) 2005-03-29
DE60116365D1 (de) 2006-02-02
HRP20030459A2 (en) 2005-04-30
AU1403402A (en) 2002-05-15
IL155191A0 (en) 2003-11-23
KR20030045167A (ko) 2003-06-09
EE200300216A (et) 2003-08-15
EA006199B1 (ru) 2005-10-27
YU33203A (sh) 2006-05-25
HUP0301710A3 (en) 2007-03-28
ATE314354T1 (de) 2006-01-15
EP1332138A1 (de) 2003-08-06
DE60116365T2 (de) 2006-08-24

Similar Documents

Publication Publication Date Title
YU33203A (sh) Radioaktivna farmaceutska sredstva za dijagnostikovanje alchajmerove bolesti
LTPA2015001I1 (lt) Tioflavino dariniai ir jų panaudojimas Alzhaimerio ligos diagnostikai ir terapijai
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
EA200201247A1 (ru) Соединения для лечения болезни альцгеймера
TW200518753A (en) Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents
EA200401114A3 (ru) Замещённые гидроксиэтиламины
GEP20053655B (en) 5-HT Receptor Ligands and Uses Thereof
GB0025173D0 (en) Therapeutic agents
TNSN06032A1 (en) Pyridazine derivatives and their use as therapeutic agents
IL188506A0 (en) Use of an immunogen for preparation of pharmaceutical composition for treating alzheimer's disease
BR0316438A (pt) Uso de eritropoietina em doenças cardìacas
GB0108592D0 (en) Therapeutic agents
EP1578385A4 (de) Zusammensetzungen und verfahren zur diagnose und behandlung von entzündlichen darmerkrankungen
BR0113838A (pt) Derivados de n-fenil-2-pirimidina-amina
ES2248356T3 (es) Compuestos para tratar la enfermedad de alzheimer.
DK0975595T3 (da) Kokainanaloger
ATE475650T1 (de) Positive allosterische chinolon-m1- rezeptormodulatoren
BR0210122A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo
CY1107850T1 (el) Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
AU3173301A (en) Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
PT1562954E (pt) Antagonistas de ccr1 para o tratamento da doenca desmielinzante inflamatoria i.a.
DE60019086D1 (de) Zusammensetzungen zur behandlung von hautkrankheiten
EP1896005A4 (de) Synergistische pharmazeutische zusammensetzungen zur prävention und behandlung von beta-amyloid-protein-induzierten erkrankungen mit verbindungen aus salbei und rosmarin
ATE464048T1 (de) Behandlung von alzheimer-krankheit und verwandten zuständen
GB0011430D0 (en) Acombination of therapeutic agents for treating Alzheimer's Disease